Trial Profile
A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary) ; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms OPTIC-2L
- Sponsors ARIAD Pharmaceuticals; Takeda Pharma
- 06 Apr 2022 This trial has been completed in Portugal, according to European Clinical Trials Database.
- 21 Jan 2021 Status changed from active, no longer recruiting to completed.
- 29 Dec 2020 This trial has been completed in Belgium, Hungary, Netherlands, Spain, Czech Republic and Austria, according to European Clinical Trials Database.